Asia Pacific Antibiotics & Antimycotics Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The Asia Pacific antibiotics and antimycotics market is projected to grow significantly, reaching approximately US$ 40,545.75 million by 2031, up from US$ 26,570.38 million in 2023, reflecting a compound annual growth rate (CAGR) of 5.4% during the forecast period from 2023 to 2031.

Executive Summary and Market Analysis

The market is divided into several key regions, including China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The growth of this market is primarily driven by the rising incidence of bacterial and fungal infections, such as pneumonia, urinary tract infections (UTIs), sexually transmitted diseases, and skin infections across the region. Additionally, strategic initiatives by market players, including new product launches and approvals, are expected to create lucrative opportunities for market expansion in the coming years.

Market Segmentation

The Asia Pacific antibiotics and antimycotics market can be analyzed through various segments, including drug class, indication, route of administration, and distribution channel:

Drug Class: The market is categorized into several drug classes, including penicillin, cephalosporins, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. In 2023, cephalosporins held the largest market share.
Indication: The market is segmented based on indications such as skin infections, respiratory infections, UTIs, septicemia, ear infections, gastrointestinal infections, and others. Skin infections accounted for the largest share in 2023.
Route of Administration: The market is divided into oral, topical, and other routes of administration, with oral administration being the most prevalent in 2023.
Distribution Channel: The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies leading the market share in 2023.

Market Outlook

The increasing awareness of fungal infections and their health implications, along with initiatives from both government and private sectors, are significant factors contributing to the growth of the antibiotics and antimycotics market. The Global Action Fund for Fungal Infections (GAFFI) reported that over 300 million people globally suffer from serious fungal diseases, leading to approximately 1.5 million deaths annually, surpassing the combined fatalities from malaria and tuberculosis. This alarming prevalence has prompted enhanced educational efforts and diagnostic initiatives, raising awareness among healthcare providers and patients about the critical need for timely treatment.

Innovations in diagnostic methods, such as molecular testing, have improved the early detection of fungal pathogens, further increasing the demand for effective antifungal treatments. GAFFI's 10-year roadmap for eliminating fungal diseases, established in 2015, outlines essential conditions for effective diagnostic delivery. Various organizations, including the International Society for Human and Animal Mycology (ISHAM) and the European Centre for Disease Prevention and Control (ECDC), are actively working to highlight the burden of fungal infections, promoting prevention, diagnosis, and treatment strategies. The annual Fungal Disease Awareness Week, observed from September 16-20, aims to raise awareness about the growing prevalence of fungal diseases and the need for appropriate responses.

Country Insights

The Asia Pacific antibiotics and antimycotics market is further analyzed by country, with China holding the largest market share in 2023. The country is witnessing a rising prevalence of fungal and bacterial infections, such as UTIs and pneumonia, which drives the demand for antibiotics and antimycotics. According to the Epidemiology and Infection Journal 2023, around 21.1 million individuals in China are affected by community-acquired pneumonia (CAP) annually. Commonly used antibiotics in China include penicillins, fluoroquinolones, cephalosporins, and nitroimidazoles.

Strategic initiatives by market players, including product launches and developments, are expected to create significant growth opportunities. For example, in September 2024, Guangzhou Sino-Israel Bio-Industry Investment Fund 2 LLP invested US$ 6.0 million in BioVersys to support clinical trials in China for BV100, targeting carbapenem-resistant Acinetobacter baumannii. In March 2023, Everest Medicines received a New Drug Application from China's National Medical Products Administration for Xerava (eravacycline) to treat complex intra-abdominal infections in adults.

Company Profiles

Key players in the antibiotics and antimycotics market include Pfizer Inc., Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc., GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc., and Astellas Pharma Inc. These companies are employing various strategies, such as expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to consumers.

Product Code: BMIRE00032106

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Asia Pacific Antibiotics and Antimycotics Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Increasing Prevalence of Infectious Diseases
- 4.1.2 Growing Awareness About Fungal Infections
4.2 Market Restraints
- 4.2.1 Antimicrobial Resistance, Financial Barriers, and Extensive Regulatory Processes
4.3 Market Opportunities
- 4.3.1 Ongoing Funding and Research & Development Initiatives
4.4 Future Trends
- 4.4.1 Technological Advancements in Product Development and Treatment Delivery Approaches
4.5 Impact of Drivers and Restraints:

5. Antibiotics and Antimycotics Market - Asia Pacific Analysis

5.1 Asia Pacific Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
5.2 Asia Pacific Antibiotics and Antimycotics Market Forecast Analysis

6. Asia Pacific Antibiotics and Antimycotics Market Analysis - by Drug Class

6.1 Penicillin
- 6.1.1 Overview
- 6.1.2 Penicillin: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.2 Cephalosporines
- 6.2.1 Overview
- 6.2.2 Cephalosporines: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.3 Carbapenems
- 6.3.1 Overview
- 6.3.2 Carbapenems: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.4 Macrolides
- 6.4.1 Overview
- 6.4.2 Macrolides: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.5 Aminoglycosides
- 6.5.1 Overview
- 6.5.2 Aminoglycosides: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.6 Quinolones
- 6.6.1 Overview
- 6.6.2 Quinolones: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.7 Sulfonamides
- 6.7.1 Overview
- 6.7.2 Sulfonamides: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.8 Tetracyclines
- 6.8.1 Overview
- 6.8.2 Tetracyclines: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.9 Azoles
- 6.9.1 Overview
- 6.9.2 Azoles: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.10 Others
- 6.10.1 Overview
- 6.10.2 Others: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Asia Pacific Antibiotics and Antimycotics Market Analysis - by Indication

7.1 Skin Infections
- 7.1.1 Overview
- 7.1.2 Skin Infections: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Respiratory Infections
- 7.2.1 Overview
- 7.2.2 Respiratory Infections: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Urinary Tract Infections (UTI)
- 7.3.1 Overview
- 7.3.2 Urinary Tract Infections (UTI): Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Septicemia
- 7.4.1 Overview
- 7.4.2 Septicemia: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Ear Infections
- 7.5.1 Overview
- 7.5.2 Ear Infections: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Gastrointestinal Infections
- 7.6.1 Overview
- 7.6.2 Gastrointestinal Infections: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.7 Others
- 7.7.1 Overview
- 7.7.2 Others: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Asia Pacific Antibiotics and Antimycotics Market Analysis - by Route of Administration

8.1 Oral
- 8.1.1 Overview
- 8.1.2 Oral: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Topical
- 8.2.1 Overview
- 8.2.2 Topical: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Asia Pacific Antibiotics and Antimycotics Market Analysis - by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Online Pharmacies
- 9.3.1 Overview
- 9.3.2 Online Pharmacies: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Asia Pacific Antibiotics and Antimycotics Market - Country Analysis

10.1 Asia Pacific
- 10.1.1 Asia Pacific Antibiotics and Antimycotics Market Overview
- 10.1.2 Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 10.1.2.1 Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 10.1.2.2 China: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.2.1 China: Asia Pacific Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.2.2 China: Asia Pacific Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.2.3 China: Asia Pacific Antibiotics and Antimycotics Market Share - by Route of Administration
    - 10.1.2.2.4 China: Asia Pacific Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 10.1.2.3 Japan: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.3.1 Japan: Asia Pacific Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.3.2 Japan: Asia Pacific Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.3.3 Japan: Asia Pacific Antibiotics and Antimycotics Market Share - by Route of Administration
    - 10.1.2.3.4 Japan: Asia Pacific Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 10.1.2.4 India: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.4.1 India: Asia Pacific Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.4.2 India: Asia Pacific Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.4.3 India: Asia Pacific Antibiotics and Antimycotics Market Share - by Route of Administration
    - 10.1.2.4.4 India: Asia Pacific Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 10.1.2.5 Australia: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.5.1 Australia: Asia Pacific Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.5.2 Australia: Asia Pacific Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.5.3 Australia: Asia Pacific Antibiotics and Antimycotics Market Share - by Route of Administration
    - 10.1.2.5.4 Australia: Asia Pacific Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 10.1.2.6 South Korea: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.6.1 South Korea: Asia Pacific Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.6.2 South Korea: Asia Pacific Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.6.3 South Korea: Asia Pacific Antibiotics and Antimycotics Market Share - by Route of Administration
    - 10.1.2.6.4 South Korea: Asia Pacific Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 10.1.2.7 Rest of APAC: Asia Pacific Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.7.1 Rest of APAC: Asia Pacific Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.7.2 Rest of APAC: Asia Pacific Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.7.3 Rest of APAC: Asia Pacific Antibiotics and Antimycotics Market Share - by Route of Administration
    - 10.1.2.7.4 Rest of APAC: Asia Pacific Antibiotics and Antimycotics Market Share - by Distribution Channel

11. Antibiotics and Antimycotics Market - Industry Landscape

11.1 Overview
11.2 Growth Strategies in Antibiotics and Antimycotics Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Pfizer Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Novartis AG
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Sanofi SA
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 F. Hoffmann-La Roche Ltd
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Merck & Co Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 GSK Plc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Johnson & Johnson
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Cipla Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Bayer AG
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 AbbVie Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
12.11 Astellas Pharma Inc
- 12.11.1 Key Facts
- 12.11.2 Business Description
- 12.11.3 Products and Services
- 12.11.4 Financial Overview
- 12.11.5 SWOT Analysis
- 12.11.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms